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Objectives In a large U.S. sample, this study measured the presentation features, testing, treatment strategies, and out-
comes of patients diagnosed with pulmonary embolism (PE) in the emergency department (ED).
Background No data have quantified the demographics, clinical features, management, and outcomes of outpatients diag-
nosed with PE in the ED in a large, multicenter U.S. study.
Methods Patients of any hemodynamic status were enrolled from the ED after confirmed acute PE or with a high clinical
suspicion prompting anticoagulation before imaging for PE. Exclusions were inability to provide informed con-
sent (where required) or unavailability for follow-up.
Results A total of 1,880 patients with confirmed acute PE were enrolled from 22 U.S. EDs. Diagnosis of PE was based
upon positive results of computerized tomographic pulmonary angiogram in most cases (n  1,654 [88%]). Pa-
tients represented both sexes equally, and racial and ethnic composition paralleled the overall U.S. ED popula-
tion. Most (79%) patients with PE were employed, and one-third were older than age 65 years. The mortality rate
directly attributed to PE was 20 in 1,880 (1%; 95% confidence interval [CI]: 0% to 1.6%). Mortality from hemor-
rhage was 0.2%, and the all-cause 30-day mortality rate was 5.4% (95% CI: 4.4% to 6.6%). Only 3 of 20 patients
with major PE that ultimately proved fatal had systemic anticoagulation initiated before diagnostic confirmation,
and another 3 of these 20 received a fibrinolytic agent.
Conclusions Patients diagnosed with acute PE in U.S. EDs have high functional status, and their mortality rate is low. These
registry data suggest that appropriate initial medical management of ED patients with severe PE with anticoagu-
lation is poorly standardized and indicate a need for research to determine the appropriate threshold for empiric
treatment when PE is suspected before diagnostic confirmation. (J Am Coll Cardiol 2011;57:700–6) © 2011
by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.05.071Pulmonary embolism (PE) is a common condition that can
cause serious morbidity or death. However, few published
reports have documented the clinical characteristics, risk
stratification methods, and treatments for suspected or
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Only 3 large multicenter registries of patients with acute PE
have been published. In aggregate, only 3% of patients in
these registries were from the United States. Moreover, no
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February 8, 2011:700–6 Outcomes of Outpatient Pulmonary Embolismprevious multicenter registry differentiated between patients
presenting acutely to an ED for evaluation of potential PE
and hospitalized patients who developed PE during an
in-patient stay (1–3).
Several issues suggest the need for a contemporary reg-
istry specific to ED patients in the United States. First,
approximately one-half of all cases of PE in the U.S. are
diagnosed in the ED (4). Second, prior PE registries have
not provided data specific to race or ethnicity. Third, data
are lacking to compare the availability and contemporaneous
se of risk stratification methods, including serum biomark-
rs, for patients diagnosed with PE. Fourth, no prior data
ave documented the frequency of use of empiric anticoag-
lation in the ED, an intervention that may affect outcome (5).
This report represents the first publication from the
MPEROR (Emergency Medicine Pulmonary Embolism
n the Real World Registry) study. The objectives of this
eport were to establish more definitively the presentation
ymptoms and signs of PE presenting in the ED setting;
haracterize treatment used by U.S. emergency physicians;
nd measure use of risk stratification methods, frequencies
f empiric anticoagulation use, and rates of major hemor-
hage and mortality among patients who present to the ED.
ethods
tudy design. EMPEROR was designed as a national,
rospective, multicenter, observational registry to character-
ze the epidemiology, presenting clinical signs and symp-
oms, ED-utilized diagnostic modalities, ED treatment,
nd 30-day outcomes of patients diagnosed with PE.
atients were enrolled from 22 community and academic EDs
Online Appendix) by site investigators who were identified on
he basis of their published experience with large, multicenter
D-based registries (6,7).
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Manuscript received February 12, 2010; revised manuscript received May 3, 2010,
accepted May 17, 2010.The study protocol was ap-
roved by the institutional review
oard at each site according to
ocal policies and procedures. The
rincipal investigators (C.V.P.,
.A.K., and S.Z.G.) were respon-
ible for the study design and
rotocol. The study was moni-
ored by a steering committee
omposed of 7 site investigators
C.V.P., J.A.K., D.H.S., D.E.S.,
.H., J.F., and B.O.) and one
ndependent consultant (S.Z.G.).
atient identification. All adult
atients age 18 years who pre-
ented to the ED with suspected
E were potentially eligible for
nclusion. Two cohorts of pa-
ients were identified. One group
ad confirmed acute PE (diag-
ostic criteria identified below).
he second group consisted of
atients with clinically suspected PE who were empirically
nticoagulated in the ED (in accordance with American
ollege of Chest Physician guidelines) before completion of
iagnostic testing but who subsequently had negative im-
ging studies, and ultimately PE was not confirmed (8).
Exclusion criteria were inability to obtain informed con-
ent (in those institutions where consent was required by the
ocal institutional review board) or evidence suggesting that
he patient would be unavailable for 30-day follow-up
homelessness, incarceration, etc).
ain measurements. Study personnel collected data from
he patient and the medical record beginning in the ED,
ncluding the hospital stay, and concluded with a review of
utcomes at 30 days. Using methodology similar to that
reviously described, data were recorded on secure Web-
ased electronic data collection forms (DCFs) designed by 2
uthors (J.A.K. and C.V.P.) (8). During the period of study
nrollment, the Web site and database were managed by an
ndependent contractor (C.L.J.) who was not affiliated with
he study sponsor. The DCF included 264 unique data
elds that were defined in advance by a data dictionary that
s included in the Online Appendix. Study personnel at each
ite were allowed to use a paper data collection template, but
ll data were ultimately entered into the Web-based DCF.
he source for all data elements was either directly from the
atient or from the medical record. Data elements collected
ncluded those necessary to calculate an ED Wells’ pretest
robability score (9); sites were encouraged and expected to
ddress the criterion “is PE the most likely diagnosis?”
rospectively (i.e., before imaging), but this was not verified
n every case.
All patients were followed for 30 days to determine
linical outcomes, including death, recurrent venous throm-
Abbreviations
and Acronyms
BNP  brain natriuretic
protein
CTPA  computerized
tomographic pulmonary
angiogram
DVT  deep venous
thrombosis
ED  emergency
department
PE  pulmonary embolism
PESI  Pulmonary
Embolism Severity Index
RV  right ventricular
SBP  systolic blood
pressure
VQ  ventilation-perfusion
VTE  venous
thromboembolismoembolism (VTE), bleeding complications, or rehospital-
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Outcomes of Outpatient Pulmonary Embolism February 8, 2011:700–6ization. Follow-up data were collected by telephone inter-
view or chart review (10). Cause of death was adjudicated by
the primary investigator at each participating center, based
upon available medical records. All clinical data, including
protocols for performing diagnostic imaging studies and the
tests used to risk-stratify PE (including troponins, natri-
uretic peptides, and echocardiography), were evaluated us-
ing local standards (11–13).
A Pulmonary Embolism Severity Index (PESI) score was
calculated for all patients for whom sufficient data was
available. The score assigns points by age, male sex (10),
presence of cancer (30), heart failure (10), chronic lung
disease (10), pulse 110 beats/min (20), systolic blood
pressure (SBP) 100 mm Hg (30), respiratory rate 30
breaths/min, temperature 36°C, altered mental status
(60), and arterial oxygen saturation90% (20). Patients
with confirmed PE with scores 85 are reported to have
higher rates of mortality (14).
Diagnostic criteria for PE. The diagnostic evaluation for
PE was entirely at the discretion of the board-certified or
board-eligible attending emergency physician directly re-
sponsible for the care of the patient. For purposes of
inclusion in the registry, the diagnosis of PE was considered
confirmed when any one of the following criteria was met:
• Computerized tomographic pulmonary angiogram
(CTPA) interpreted by the attending radiologist as
positive for PE, based on accepted radiologic criteria
• High-probability nuclear ventilation-perfusion (VQ)
lung scan
• Pulmonary angiogram interpreted as positive for PE
• Pulmonary vascular magnetic resonance angiography
interpreted as positive for PE
• Deep venous thrombosis (DVT) on a duplex ultra-
sound of the lower or upper extremities performed
within 30 days before enrollment, in association with
Figure 1 Flow Diagram of Enrolled Patients in the EMPEROR T
The flow diagram shows the outcome of all enrolled patients with respect to diagn
DVT  deep venous thromboembolism; PE  pulmonary embolism.chest pain or shortness of breath tSample size. The sample size was based on pre-planned
subgroup analyses and a planned total enrollment of at least
2,250 patients, assuming that 80% would have confirmed
PE. We aimed to narrow the 95% confidence interval (CI)
around the in-hospital mortality rate to less than 5% for
patients with confirmed PE, which was estimated from
existing reports in 2006 to be 10% (15,16). Patients without
PE were enrolled only if during their real-time ED evalu-
ation they were deemed to be of sufficiently high clinical risk
for PE to initiate empiric full-dose anticoagulation therapy
in the ED before pulmonary vascular imaging, which
subsequently was negative for PE.
Analysis. Frequency data are presented as proportions with
associated 95% CI, calculated by the exact binomial
method. Continuous data are shown as means with associ-
ated SD. We did not report any specific hypothesis-testing
p values.
Results
Over 26 months (from January 1, 2005, to December 29,
2008), 2,408 patients were enrolled, including 1,880 (78%)
patients with confirmed PE (Fig. 1). This report focuses on
these 1,880 patients with acute PE. The diagnosis of PE
was based upon positive results of CTPA (n  1,654),
iagnostic VQ scan (n  82), formal pulmonary angiogra-
hy (n  91), DVT with appropriate PE symptoms (n 
1), or positive pulmonary magnetic resonance angiography
n  2).
linical characteristics. Tables 1 to 3 present the demo-
raphic, risk factors, and clinical features of the study
opulations with and without confirmed PE. Definitions of
isk factors are included in the Online Appendix. The mean
ge was 57  18 years, with a slight majority of women
53%; 95% CI: 50.5% to 55.0%); the majority of patients
ere Caucasian (68%). The mean vital sign data suggested
f venous thromboembolism.rial
osis ohat the PE population manifested no significant differences
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February 8, 2011:700–6 Outcomes of Outpatient Pulmonary Embolismfrom the PE-negative group (17). Only 58 (3.0%) patients
had SBP 90 mm Hg at presentation. The most common
resenting signs and symptoms were dyspnea at rest (50%),
leuritic chest pain (39%), dyspnea with exertion (27%), and
xtremity swelling suggestive of DVT (24%). Consistent
ith other studies, only 5% of patients with PE presented
ith syncope (1–3).
Clinical features and comorbid conditions relevant to
edical decision making for the diagnosis and treatment of
E are described in Table 2. The most common comor-
bidities that could represent potential risk factors for PE
were hypertension (46%), obesity (27%), recent hospitaliza-
tion (24%), and active malignancy (22%). Based on the
absence of any of these 28 predefined risk factors for PE
(Online Appendix), 312 of the 1,880 (16.5%) patients were
considered to have idiopathic PE. In response to the specific
criterion of the Wells’ PE pre-test probability score (was PE
the most likely diagnosis at the time that the evaluation was
initiated?), clinicians indicated that they believed that 1,572
of 1,880 (84%) of PE-positive patients had PE as their most
likely pre-test diagnosis. The mean Wells’ score was 3.0 
1.7 (median 2.5). The distribution of scores by low (2),
moderate (2 to 6), and high (6) pre-test probability values
were 40.2%, 54.3%, and 5.5%, respectively.
Risk stratification. A quantitative D-dimer was performed
in 543 (29%) and was elevated (per local lab normal range)
in the majority (477 of 543 [87%]), with a mean value of
7,162  14,241 ng/ml (median 2,125 ng/ml; 1st to 3rd
quartiles 896 to 5,327 ng/ml). Transthoracic echocardiog-
raphy was performed on 430 of 1,880 patients (23%),
revealing right ventricular (RV) hypokinesis in 218 (51% of
those imaged). A serum troponin assay was performed in
1,287 (68%) patients, revealing an elevated value (compared
with local normal range) in 424 (33% of those tested). A
serum brain natriuretic peptide (BNP) or NT-proBNP
measurement was obtained in 661 (35%), revealing an
elevated value in 207 (31% of those tested). In aggregate,
661 of 1,880 (35%) patients with confirmed PE manifested
Age, Sex, Race, andEthnicity of Registry ParticipantsTable 1 Age, Sex, Ra e, andEthnicity of Registry Participants
Demographic Feature
Confirmed PE
(n  1,880)
PE Not Confirmed
(n  528)
Mean age, yrs (SD) 56.5 (18.1) 55.9 (18.0)
Age 65 yrs 631 (33.5) 159 (30.1)
Female sex 992 (52.8) 304 (57.6)
Race/ethnicity
Caucasian 1284 (68.3) 312 (59.1)
African American 482 (25.6) 161 (30.5)
Hispanic 57 (3.0) 29 (5.5)
Asian 11 (0.6) 3 (0.6)
Unknown 17 (0.9) 10 (1.9)
Other 29 (1.5) 13 (2.5)
Values are n (%).
PE  pulmonary embolism.at least 1 of the following predictors of an adverse outcome pwhile in the ED: echocardiography (performed in the ED)
with RV hypokinesis, elevated troponin level, or elevated
BNP or NT-proBNP level. The mean value of the PESI
score for patients with confirmed PE was 88  34, with a
range from 18 to 215 (17).
Functional status. The ED clinicians categorized enrolled
patients into one of 4 categories of functional status upon
presentation, as listed in Table 4. The primary finding was
that most (79%) patients diagnosed with PE in the ED were
independent and employed.
Treatments and outcomes. Systemic non–vitamin K–de-
pendent anticoagulation was initiated in the ED in 1,593 of
1,880 (84%) patients, with unfractionated heparin (n 
98), enoxaparin (n  671), fondaparinux (n  23), or
alteparin (n  1). However, heparin of any type was
dministered before the results of diagnostic imaging to
nly 173 of 1,880 (9%) patients who had confirmed PE.
ased upon the Wells’ score, the pre-test probabilities were
ow in 44 (25%), moderate in 111 (65%), and high in 18
10%). A fibrinolytic agent was administered in the ED to
3 patients (alteplase n  29 and tenecteplase n  4), 3
Risk Factors for PE and Comorbid Conditions*Table 2 Risk Factors for PE and Comorbid Conditions*
Feature
Confirmed PE
(n  1,880)
PE Not Confirmed
(n  528)
Hypertension 857 (45.6) 274 (51.9)
Obesity 505 (26.9) 140 (26.5)
Recent hospitalization 448 (23.8) 97 (18.4)
Malignancy, active 419 (22.3) 96 (18.2)
Current smoker 332 (17.7) 99 (18.8)
Recent surgery 271 (14.4) 38 (7.2)
Prior DVT 224 (11.9) 103 (19.5)
Current DVT 178 (9.5) 36 (6.8)
Prior PE within 3 months 60 (3.2) 50 (9.5)
Immobility 218 (11.6) 31 (5.9)
Prior PE 3 months 172 (9.1) 86 (16.3)
COPD 159 (8.5) 66 (12.5)
Family history of DVT or PE 157 (8.4) 23 (4.4)
History of heart failure 141 (7.5) 61 (11.6)
Coronary artery disease with
prior myocardial infarction
128 (6.8) 36 (6.8)
Malignancy, in remission 108 (5.7) 40 (7.6)
Limb immobilization 96 (5.1) 6 (1.1)
In-dwelling venous catheter 91 (4.8) 32 (6.1)
Recent significant trauma 88 (4.7) 11 (2.1)
Oral contraceptives 83 (4.4) 8 (1.5)
Known genetic prothrombotic
state
70 (3.7) 21 (4.0)
Neurologic paralysis 53 (2.8) 14 (2.7)
Estrogen replacement therapy 24 (1.3) 5 (0.9)
History of lupus erythematosus 16 (0.9) 12 (2.3)
Postpartum 16 (0.9) 2 (0.4)
Pregnancy 14 (0.7) 4 (0.8)
History of sickle cell disease 12 (0.6) 4 (0.8)
Connective tissue disease 12 (0.6) 2 (0.4)
Values are n (%). *See Online Appendix for definitions.
COPD  chronic obstructive pulmonary disease; DVT  deep venous thrombosis; PE 
ulmonary embolism.
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Outcomes of Outpatient Pulmonary Embolism February 8, 2011:700–6(9.1%) of whom had hypotension upon ED arrival; an
additional 12 patients received alteplase after admission.
Table 5 presents the primary outcomes data. The mor-
ality rate directly attributed to PE in the patients with
onfirmed PE was 1.1% (20 of 1,880; 95% CI: 0% to 1.6%).
welve of these 20 patients manifested at least 1 high-risk
redictor of an adverse outcome while in the ED, including
Signs and Symptoms at PresentationTable 3 Signs and Symptoms at Presentation
Feature
Confirmed PE
(n  1,880)
PE Not Confirmed
(n  528)
Vital signs at presentation in ED
Heart rate, beats/min* 95.7 (20.5) 93.8 (21.8)
Respiratory rate, breaths/min* 20.5 (5.2) 21.2 (7.7)
Systolic blood pressure, mm Hg* 132.3 (24.8) 137.1 (26.7)
Oxygen saturation, %* 95.3 (5.4) 95.7 (5.6)
Symptoms reported by patient
Dyspnea at rest 942 (50.1) 268 (50.8)
Pleuritic chest pain 740 (39.4) 150 (28.4)
Dyspnea with exertion 507 (27.0) 88 (16.7)
Cough without hemoptysis 430 (22.9) 121 (22.9)
Substernal chest pain 285 (15.2) 90 (17.0)
Dizziness 230 (12.2) 51 (9.7)
Diaphoresis 220 (11.7) 70 (13.3)
Upper abdominal pain 202 (10.7) 39 (7.4)
Fever 182 (9.7) 52 (9.8)
Cough with hemoptysis 143 (7.6) 24 (4.5)
Unilateral extremity pain 110 (5.9) 28 (5.3)
Syncope 103 (5.5) 30 (5.7)
Altered mental status 90 (4.8) 29 (5.5)
Angina 74 (3.9) 20 (3.8)
Physical findings in ED
Extremity swelling suggestive of DVT 442 (23.5) 97 (18.4)
Respiratory distress 309 (16.4) 71 (13.4)
Rales 158 (8.4) 32 (6.1)
Diaphoresis 133 (7.1) 28 (5.3)
Chest radiograph findings
Normal 545 (40.1) 161 (40.7)
Westermark sign 5 (0.4) 1 (0.3)
Hampton hump 11 (0.8) 1 (0.3)
Atelectasis 230 (16.9) 61 (15.4)
Infiltrate 184 (13.5) 55 (13.9)
Pleural effusion 220 (16.2) 55 (13.9)
Elevated hemidiaphragm 34 (2.5) 7 (1.8)
Cardiomegaly 162 (11.9) 51 (12.9)
Stable non-PE pathology 197 (14.4) 59 (14.9)
Values are n (%). *Data are presented as mean (SD).
ED  emergency department; other abbreviations as in Table 2.
Functional Status and Comorbid ConditionsTable 4 Functional Status and Comorbid Co
Functional Status
All Patients
(n  2,408)
Dependent upon caregivers 174 (7.2)
Dependent upon family 180 (7.4)
Independent but disabled 174 (7.2)
Independent employed 1,880 (78.1)Values are n (%).
PE  pulmonary embolism.arterial SBP 90 mm Hg (n  4), elevated troponin
concentration (n  6), or RV hypokinesis observed on
echocardiography (n  2). Based upon the Wells’ score, the
pre-test probabilities of these 20 were low in 6 (30%),
moderate in 14 (70%), and high in 0 (0%). In these patients,
the choice of initial anticoagulant was unfractionated hep-
arin in 12 (60%), enoxaparin in 7 (35%), and fondaparinux
in 1 (5%); however, only 3 received acute anticoagulation
before imaging, and 3 others received fibrinolytic therapy
more than 2 hours after the diagnosis was established. Three
patients (0.2%) died from hemorrhage during their initial
hospitalization; none of these received fibrinolysis during
their hospitalization. The all-cause mortality rate at 30 days
was 102 of 1,880 (5.4%; 95% CI: 4.4% to 6.5%) in the
PE-confirmed cohort. Of all patients who died from any
cause, 87% had PESI scores 84, whereas only 42% of
survivors had PESI scores 84.
Discussion
This report presents key findings from the first large
multicenter registry specifically designed to quantify clinical
characteristics and outcomes of patients with PE diagnosed
in an ED setting.
These results quantify a surprisingly low mortality rate
for patients diagnosed with PE in the ED setting. In
contrast to the 10% to 15% mortality rate that has been
found in previous registries, the data from EMPEROR
suggest a remarkably low in-hospital mortality rate di-
rectly attributable to PE of 1.1% (95% CI: 0.0% to 1.6%)
and an all-cause mortality rate at 30 days of only 5.4%
(95% CI: 4.4% to 6.5%). The all-cause mortality rate
within 14 days after diagnosis of PE (primarily in the
in-patient environment) in the ICOPER (International
Cooperative Pulmonary Embolism Registry) study was
11.2% (95% CI: 10.0% to 12.5%), and the RIETE
(Registro Informatizado de la Enfermedad TromboEm-
bo´lica) study reported an approximate 30-day mortality
directly attributable to PE (among 6,518 patients with
confirmed PE) of 3.3% (95% CI: 2.9% to 3.8%). Impor-
tantly, our data are consistent with the 2007 National ED
Survey, which reported a 3.3% in-hospital mortality rate
for 121,026 ED patients diagnosed with PE (4).
The low mortality rate probably reflects several factors.
First, this registry included only outpatients who suffered
PE, and the data suggested that this population was younger
ns
Confirmed PE
(n  1,880)
PE Not Confirmed
(n  528)
137 (7.3) 37 (7.0)
134 (7.1) 46 (8.7)
123 (6.5) 51 (9.7)
1,486 (79.0) 394 (74.6)nditio
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February 8, 2011:700–6 Outcomes of Outpatient Pulmonary Embolismand less ill than were populations enrolled in prior registries
that included in-patients. For example, the mean patient in
the present study was 56.5 years, compared with the mean
age of 62 and 66 years in the ICOPER and RIETE
registries, respectively. Almost one-third of our sample was
non-Caucasian, a predictor of worsened outcome for many
acute cardiovascular illnesses. The present study was con-
ducted in the era of CTPA scanning as the primary
diagnostic modality, raising the speculative point that diag-
nosis and treatment may have been faster than when VQ
scanning was the primary method of diagnosis. Lastly, the
present registry reflected an increased use of low-molecular-
weight heparin and pentasaccharide anticoagulants, which
may have affected mortality.
Our data do suggest an opportunity for better stan-
dardization of treatment. For example, of the 20 patients
who died from PE, only 3 received anticoagulation before
diagnostic confirmation of PE, even though none of the
20 had a documented contraindication to anticoagula-
tion. Prior work has suggested that delays in anticoagu-
lation are associated with increased short-term adverse
events, including recurrence of VTE (18,19). Two inde-
pendent reports have found an increase in mortality in
ED patients with PE who did not receive heparin until
after hospital admission, compared with patients who
received heparin in the ED (5,18,19). Moreover, Smith
et al. (5) found that the time to heparin administration
was an independent predictor of mortality in a logistic
regression equation that was adjusted for the cumulative
effect of comorbidities. Furthermore, in the present
study, of 20 patients who died of PE, only 3 received
fibrinolytic therapy in the ED. The variable application
of fibrinolytic therapy in the ED, compared with con-
temporary, evidence-based guideline recommendations,
are both cause for concern and an opportunity for a future
randomized, controlled trial of empiric heparin versus no
anticoagulation prior to confirmatory imaging (8,20).
Other significant findings included that 79% of ED
patients with PE were employed and capable of indepen-
dent living. Only 11.6% reported generalized immobility,
and only one-third were older than 65 years. These obser-
vations may be surprising because most published reports
In-Hospital and 30-Day OutcomesTable 5 In-Hospital and 30-Day Outcomes
Feature
Confirmed PE
(n  1,880)
PE Not Confirmed
(n  528)
All-cause mortality in-hospital 63 (3.4) 22 (4.2)
Death from PE 20 (1.1) 6 (1.1)
Death from hemorrhage 3 (0.16) 1 (0.19)
Death from other 40 (2.1) 15 (2.8)
All-cause death within 30 days 102 (5.4) 37 (7.0)
Recurrent PE within 30 days 49 (2.6) 10 (1.9)
New DVT within 30 days 11 (0.58) 2 (0.38)
Values are n (%).
Abbreviations as in Table 2.suggest that “typical” patients with PE have chronic orincurable disease, are of advanced age, or are bed-bound.
Our findings emphasize the point that emergency physi-
cians should not limit their consideration of the diagnosis to
“typical” presentations (1–3).
Idiopathic PE was diagnosed in only 312 (16%), and all
but 24 (1.3%) of these patients had tachycardia (heart rate
100 beats/min), had hypoxemia (SaO2 95%), or were
65 years of age. Thus, the clinician need not be overly
concerned that many young ED patients are diagnosed with
PE in the presence of no risk factors and normal vital signs.
These data also reported the novel finding that patients
diagnosed with PE have an ethnic and racial distribution
that closely parallels that of all patients who present to U.S.
EDs (21).
Finally, we observed a balanced sex distribution for
patients diagnosed with, or empirically treated for, PE. This
finding is remarkable because a previous large multicenter
U.S.-based study of ED patients found that clinicians
evaluated female patients with pulmonary vascular imaging
twice as often as male patients (22).
These data should be useful to clinicians and researchers.
Clinicians can use these data to inform ED patients that, in
general, the prognosis of PE with respect to survival is good.
Researchers may find the mortality rate particularly impor-
tant in designing treatment studies centered in the ED. For
example, if a researcher wishes to test the effect of a
treatment on mortality in patients presenting with PE in the
ED, our data indicated that a large sample size will be
needed to produce a statistically significant reduction in
mortality rate directly attributable to PE.
Study limitations. All registries have some degree of sys-
tematic sampling bias. We believe the primary source of bias
in this study was related to the lack of certainty that our
sample was a truly random or representative sample of PE
presenting in the ED. Although the present study enrolled
patients regardless of hemodynamic stability, only 58 of
1,880 (3%) patients were hypotensive at presentation. How-
ever, given that this is about the same proportion of
hypotensive patients with massive PE as was found in
ICOPER (2), another, more likely possibility is that the
massive PE rate, with “massive” defined as hypotensive PE,
is approximately 3%. It should also be noted that we
collected only presentation vital signs, without subsequent
serial data; patients who became hypotensive only later in
the ED or after admission would not be recognized as
“hypotensive” in the database.
Conclusions
Patients with acute PE diagnosed in U.S. EDs had a low
all-cause mortality rate of 5.4% at 30 days. Acute anticoag-
ulation with a heparinoid was administered relatively late in
the care of patients with fatal PE. These data suggested that
empiric anticoagulation in patients with suspected PE
should be instituted more often in the ED and that timely,
therapeutic anticoagulation should be administered after the
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conducted in U.S. EDs should focus on accelerating the
time frame of administration of systemic anticoagulation
and fibrinolysis to patients with evidence of severe PE. The
low mortality rate also implied that efficacy aims for treat-
ment studies should probably measure composite end points
that include recurrent VTE, complications of anticoagula-
tion including bleeding, and perhaps other patient-oriented
end points associated with quality of life.
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APPENDIX:
For participating sites and lists of definitions and exclusions,
please see the online version of this article.
